Influence of noliprel A forte and Valsaforsa on renal function in patients with chronic glomerulonephritis and arterial hypertension
The study included 40 patients with chronic glomerulonephritis and arterial hypertension who were randomized into 2 groups. Patients of the first group were taking noliprel A fort (® Servier), the second group - valsafors (Promo-Med). The drugs were prescribed for 2 months period. If the antihypertensive effect after 1 month was insufficient the dose of each drug was doubled. Clinical efficiency of antihypertensive therapy was assessed by daily monitoring of blood pressure, biochemical parameters of blood, indicators of renal function (sample of Rehberg Tareev, Cockcroft-Gault and MDRD) before and after 8 weeks of therapy. The therapy of that drugs significantly reduced the level of blood pressure, improved the circadian profiles of blood pressure, metabolic neutrality. Treatment by noliprel A forte has resulted in substantial improvement in the circadian profiles of blood pressure, significantly improved renal function on the sample of Rehberg Tareev at 20 ml / min ± 0,56, on the formula of Cockcroft-Gault at 7 ml / min ± 0,36, according to the MDRD formula 6 ml/min/1, 73 m2 ± 0,16.